adrenergic beta antagonists

Summary

Summary: Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Top Publications

  1. ncbi Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure
    Kamala P Tamirisa
    Department of Internal Medicine, Women s L3623 0271, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Am Heart J 148:971-8. 2004
  2. ncbi Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy
    Stefano Ghio
    Division of Cardiology, IRCCS Policlinico San Matteo, Pavia, Italy
    Eur Heart J 27:562-8. 2006
  3. pmc A genetic analysis of opioid-induced hyperalgesia in mice
    De Yong Liang
    Department of Anesthesiology, Stanford University, Palo Alto, California, USA
    Anesthesiology 104:1054-62. 2006
  4. ncbi Characteristics and outcomes of patients with heart failure in general practices and hospitals
    Hiroyuki Tsutsui
    Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine
    Circ J 71:449-54. 2007
  5. pmc Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension
    Ali Jawa
    King Edward Medical University, Lahore, Pakistan
    J Diabetes Complications 22:303-8. 2008
  6. ncbi Optimal medical therapy with or without PCI for stable coronary disease
    William E Boden
    Western New York Veterans Affairs Healthcare Network and Buffalo General Hospital SUNY, Buffalo, NY 14203, USA
    N Engl J Med 356:1503-16. 2007
  7. ncbi The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment
    M Komajda
    Eur Heart J 24:464-74. 2003
  8. ncbi Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina
    Jean Claude Tardif
    Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada
    Eur Heart J 26:2529-36. 2005
  9. ncbi Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B
    Bjorn Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Lancet 366:895-906. 2005
  10. ncbi Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial
    H J Dargie
    Department of Cardiology, Western Infirmary, G11 2NT, Glasgow, UK
    Lancet 357:1385-90. 2001

Detail Information

Publications252 found, 100 shown here

  1. ncbi Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure
    Kamala P Tamirisa
    Department of Internal Medicine, Women s L3623 0271, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Am Heart J 148:971-8. 2004
    ..We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone...
  2. ncbi Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy
    Stefano Ghio
    Division of Cardiology, IRCCS Policlinico San Matteo, Pavia, Italy
    Eur Heart J 27:562-8. 2006
    ..An echocardiographic substudy was designed to evaluate the effects of nebivolol on systolic and diastolic left ventricular (LV) function in patients stratified according to the presence or absence of systolic LV dysfunction...
  3. pmc A genetic analysis of opioid-induced hyperalgesia in mice
    De Yong Liang
    Department of Anesthesiology, Stanford University, Palo Alto, California, USA
    Anesthesiology 104:1054-62. 2006
    ..This syndrome may reduce the clinical utility of opioids in treating acute and chronic pain...
  4. ncbi Characteristics and outcomes of patients with heart failure in general practices and hospitals
    Hiroyuki Tsutsui
    Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine
    Circ J 71:449-54. 2007
    ..However, very little information is available on this issue in general practice in Japan...
  5. pmc Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension
    Ali Jawa
    King Edward Medical University, Lahore, Pakistan
    J Diabetes Complications 22:303-8. 2008
    ..We studied the effects of beta-blockers addition and comparative effects of carvedilol with metoprolol on 24-h urinary-albumin excretion (UAE) and endothelial function (EF) in AA with PMA...
  6. ncbi Optimal medical therapy with or without PCI for stable coronary disease
    William E Boden
    Western New York Veterans Affairs Healthcare Network and Buffalo General Hospital SUNY, Buffalo, NY 14203, USA
    N Engl J Med 356:1503-16. 2007
    ....
  7. ncbi The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment
    M Komajda
    Eur Heart J 24:464-74. 2003
    ..Accordingly, the Euro Heart Failure Survey was conducted to ascertain how patients hospitalized for heart failure are managed in Europe and if national variations occur in the treatment of this condition...
  8. ncbi Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina
    Jean Claude Tardif
    Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada
    Eur Heart J 26:2529-36. 2005
    ..Ivabradine has shown anti-ischaemic and anti-anginal activity in a placebo-controlled trial. The objective of this study was to compare the anti-anginal and anti-ischaemic effects of ivabradine and the beta-blocker atenolol...
  9. ncbi Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B
    Bjorn Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Lancet 366:895-906. 2005
    ..Our aim, therefore, was to compare the effect on non-fatal myocardial infarction and fatal CHD of combinations of atenolol with a thiazide versus amlodipine with perindopril...
  10. ncbi Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial
    H J Dargie
    Department of Cardiology, Western Infirmary, G11 2NT, Glasgow, UK
    Lancet 357:1385-90. 2001
    ..We investigated the long-term efficacy of carvedilol on morbidity and mortality in patients with left-ventricular dysfunction after acute myocardial infarction treated according to current evidence-based practice...
  11. ncbi Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators
    M R Bristow
    Division of Cardiology, University of Colorado HSC, Denver 80262, USA
    Circulation 94:2807-16. 1996
    ..We conducted a multicenter, placebo-controlled trial designed to establish the efficacy and safety of carvedilol, a "third-generation" beta -blocking agent with vasodilator properties, in chronic heart failure...
  12. ncbi Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications
    Joana Mascarenhas
    Servico de Medicina Interna, Hospital S Joao, Porto, Portugal
    Am Heart J 155:521-5. 2008
    ..We aimed to assess the prevalence and prognostic implications of COPD in a sample of stable patients with HF and to determine the frequency of beta-blocker (bB) use and rate of withdrawal according to COPD coexistence...
  13. ncbi Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial
    Anders Heijl
    Department of Ophthalmology, Malmo University Hospital, SE 20502 Malmo, Sweden
    Arch Ophthalmol 120:1268-79. 2002
    ..To provide the results of the Early Manifest Glaucoma Trial, which compared the effect of immediately lowering the intraocular pressure (IOP), vs no treatment or later treatment, on the progression of newly detected open-angle glaucoma...
  14. ncbi Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure
    Steven Reiken
    Center for Molecular Cardiology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Circulation 107:2459-66. 2003
    ..6. We tested the hypothesis that improved cardiac muscle function attributable to beta-AR blockade is associated with restoration of normal RyR2 channel function in patients with heart failure...
  15. ncbi beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality
    Kevin C Abbott
    Nephrology Service, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Arch Intern Med 164:2465-71. 2004
    ....
  16. pmc A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling
    James W Wisler
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 104:16657-62. 2007
    ..We hypothesize that such signaling may contribute to the special efficacy of carvedilol in the treatment of heart failure and may serve as a prototype for a new generation of therapeutic beta2AR ligands...
  17. ncbi Expert consensus document on beta-adrenergic receptor blockers
    Jose Lopez-Sendon
    Cardiology, Hospital Universitario Gregorio Maranon, Madrid, Spain
    Eur Heart J 25:1341-62. 2004
  18. ncbi Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome
    A J Moss
    Department of Medicine, University of Rochester School of Medicine and Dentistry, NY 14642, USA
    Circulation 101:616-23. 2000
    ..beta-blockers are routinely prescribed in congenital long-QT syndrome (LQTS), but the effectiveness and limitations of beta-blockers in this disorder have not been evaluated...
  19. ncbi Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial
    P Lechat
    Pharmacology Department, Pitie Salpetriere Hospital, Paris, France
    Circulation 103:1428-33. 2001
    ..beta-Blockade-induced benefit in heart failure (HF) could be related to baseline heart rate and treatment-induced heart rate reduction, but no such relationships have been demonstrated...
  20. ncbi Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study
    Lars Rejnmark
    Department of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus Sygehus, Aarhus, Denmark
    J Hypertens 24:581-9. 2006
    ..Antihypertensive drugs may increase the risk of falling. However, risk of fracture in patients treated with non-diuretic cardiovascular drugs is largely unknown...
  21. ncbi Leptin regulates bone formation via the sympathetic nervous system
    Shu Takeda
    Department of Molecular and Human Genetics, One Baylor Plaza, Houston, TX 77030, USA
    Cell 111:305-17. 2002
    ..None of these manipulations affects body weight. This study demonstrates a leptin-dependent neuronal regulation of bone formation with potential therapeutic implications for osteoporosis...
  22. pmc Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene
    Arthur J Moss
    Cardiology Division, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Circulation 115:2481-9. 2007
    ..We evaluated the effect of location, coding type, and biophysical function of KCNQ1 mutations on the clinical phenotype of this disorder...
  23. pmc Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial
    Jean Claude Tardif
    Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, Canada
    Eur Heart J 30:540-8. 2009
    ..To evaluate the anti-anginal and anti-ischaemic efficacy of the selective I(f) current inhibitor ivabradine in patients with chronic stable angina pectoris receiving beta-blocker therapy...
  24. ncbi Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas
    D L Weddle
    Carcinogenesis and Developmental Therapeutics Program, College of Veterinary Medicine, University of Tennessee, 2407 River Drive, Knoxville, TN 37996, USA
    Carcinogenesis 22:473-9. 2001
    ....
  25. ncbi Heart rate variability in myocardial infarction and heart failure
    Nipon Chattipakorn
    Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
    Int J Cardiol 120:289-96. 2007
    ..In this article, the current role of HRV in the prediction of cardiovascular mortality in myocardial infarction and heart failure patients has been reviewed...
  26. ncbi Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein
    C Communal
    Myocardial Biology Unit and Cardiovascular Division, Boston University Medical Center, Boston Veterans Affairs Medical Center and Boston University School of Medicine, Boston, MA, USA
    Circulation 100:2210-2. 1999
    ..beta(2)-ARs may couple to a G(i)-mediated signaling pathway that can oppose the actions of adenylyl cyclase...
  27. ncbi Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol
    Shu Kasama
    Department of Cardiovascular Medicine, Gunma University School of Medicine, 3 39 15, Showa machi, Maebashi, Gunma 371 0034, Japan
    Eur Heart J 28:989-95. 2007
    ..However, the influence of carvedilol on cardiac (123)I-meta-iodobenzylguanidine (MIBG) scintigraphic findings and left ventricular (LV) remodelling has not been determined in DCM patients...
  28. ncbi Resting heart rate in cardiovascular disease
    Kim Fox
    Royal Brompton Hospital, Sydney Street, London SW3 6NP, England
    J Am Coll Cardiol 50:823-30. 2007
    ..These findings suggest that the potential role of HR and its modulation should be considered in future cardiovascular guidance documents...
  29. ncbi Long QT syndrome in adults
    Andrew J Sauer
    Cardiology Unit of the Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642 8653, USA
    J Am Coll Cardiol 49:329-37. 2007
    ....
  30. ncbi Comparison of the chronotropic response to exercise and heart rate recovery in predicting cardiovascular mortality
    Jonathan Myers
    Cardiology Division, Veterans Affairs Palo Alto Health Care System, Stanford University, Palo Alto, CA 94304, USA
    Eur J Cardiovasc Prev Rehabil 14:215-21. 2007
    ..It is, however, unknown which of these responses more powerfully predicts risk, and few data are available on their association with cardiovascular mortality or how they are influenced by beta-blockade...
  31. ncbi Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers
    Genevieve Flannery
    Clinical Pharmacology Unit, Alfred Hospital, Melbourne, Australia
    Am J Cardiol 101:865-9. 2008
    ..Therefore, the magnitude of HR reduction may be more important than the achievement of target dose in beta-blocker treatment of systolic CHF...
  32. ncbi Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study
    Julie A Pasco
    Department of Clinical and Biomedical Sciences Barwon Health, The University of Melbourne, Geelong, Australia
    J Bone Miner Res 19:19-24. 2004
    ..49-0.96). Beta-blockers were associated with higher BMD at the total hip (2.5%) and UD forearm (3.6%) after adjusting for age, anthropometry, and thiazide use. Beta-blocker use is associated with reduced fracture risk and higher BMD...
  33. ncbi Beta-adrenergic modulation of cognitive flexibility during stress
    Jessica K Alexander
    The Ohio State University, Columbus, OH 43210, USA
    J Cogn Neurosci 19:468-78. 2007
    ..This may provide support for the hypothesis that stress-related impairments in cognitive flexibility are related to the noradrenergic system...
  34. ncbi Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters
    H M Schuller
    Experimental Oncology Laboratory, College of Veterinary Medicine, University of Tennessee, Knoxville 37906, USA
    J Cancer Res Clin Oncol 126:624-30. 2000
    ..We have recently shown that the growth of cell lines derived from human PACs is controlled by beta-adrenergic receptors, and that NNK is a high affinity agonist for this receptor family...
  35. ncbi The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies
    Peter C Austin
    Institute for Clinical Evaluative Sciences, G1 06, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5 Canada
    Med Decis Making 29:661-77. 2009
    ..In the Monte Carlo simulations, propensity score matching tended to have either comparable or marginally superior performance compared with propensity-score weighting...
  36. ncbi Erythrocyte G protein-coupled receptor signaling in malarial infection
    Travis Harrison
    Department of Pathology, Feinberg School of Medicine, Northwestern University, 303 Chicago Avenue, Chicago, IL 60611, USA
    Science 301:1734-6. 2003
    ..berghei infections in an in vivo mouse model. Thus, signaling via the erythrocyte beta2-adrenergic receptor and Galphas may regulate malarial infection across parasite species...
  37. ncbi Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III
    Ronnie Willenheimer
    Department of Cardiology, University Hospital, Lund University, Malmo, Sweden
    Circulation 112:2426-35. 2005
    ..In patients with chronic heart failure (CHF), a beta-blocker is generally added to a regimen containing an angiotensin-converting-enzyme (ACE) inhibitor. It is unknown whether beta-blockade as initial therapy may be as useful...
  38. ncbi Are antihypertensive drugs associated with abdominal aortic aneurysms?
    Antonius B M Wilmink
    Department of Vascular Surgery, Birmingham Heartlands Hospital, Birmingham, UK
    J Vasc Surg 36:751-7. 2002
    ..Aortic elasticity was measured by M-mode ultrasound scanning. A serum radioimmunoassay of the amino-terminal propeptide of type III procollagen was used to assess collagen turnover in one of the patient series...
  39. ncbi Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers
    Silvia G Priori
    Molecular Cardiology, IRCCS Fondazione Maugeri, University of Pavia, Pavia, Italy
    JAMA 292:1341-4. 2004
    ..Data on the efficacy of beta-blockers in the 3 most common genetic long QT syndrome (LQTS) loci are limited...
  40. ncbi Hospital-level performance improvement: beta-blocker use after acute myocardial infarction
    Elizabeth H Bradley
    Section of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Med Care 42:591-9. 2004
    ....
  41. ncbi Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure
    Frederick A Masoudi
    Division of Cardiology, Denver Health Medical Center, Denver, Colo 80204, USA
    Am Heart J 146:250-7. 2003
    ..Our objective was to determine the proportion of older persons meeting enrollment criteria of randomized controlled trials of agents that prolong life in heart failure...
  42. ncbi Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)
    Michel Komajda
    Institut de Cardiologie, Centre Hospitalier GH Pitié Salpêtrière, 47 83 bld de l Hôpital, 75013, Paris Cedex 13, France
    Eur J Heart Fail 6:467-75. 2004
    ..Management guidelines for heart failure recommend ACE-I and beta-blockers. The perception of difficult up-titration might have added to the slow uptake of beta-blockers despite their mortality and morbidity benefits...
  43. ncbi Beta-blockers in congestive heart failure. A Bayesian meta-analysis
    J M Brophy
    Service de cardiologie, Centre Hospitalier de l Universite de Montreal, Pavillon Notre Dame, 1560 rue Sherbrooke Est, Montreal, Quebec H2L 4M1, Canada
    Ann Intern Med 134:550-60. 2001
    ..Although several randomized clinical trials have compared beta-blockers with placebo for treatment of congestive heart failure, a meta-analysis quantifying the effect on mortality and morbidity has not been performed recently...
  44. ncbi A comparison of atenolol and nebivolol in isolated systolic hypertension
    Zahid Dhakam
    Clinical Pharmacology Unit, University of Cambridge, Addenbrooke s Hospital, Cambridge, CB2 2QQ, UK
    J Hypertens 26:351-6. 2008
    ..The aim of the present study was to test this in a double-blind, randomized, cross-over study, in a cohort of subjects with isolated systolic hypertension...
  45. ncbi Adverse prognostic significance of new diabetes in treated hypertensive subjects
    Paolo Verdecchia
    Dipartimento Malattie Cardiovascolari, Universita di Perugia, Ospedale R Silvestrini S Andrea delle Fratte 06122 Perugia, Italy
    Hypertension 43:963-9. 2004
    ..In treated hypertensive subjects, occurrence of new diabetes portends a risk for subsequent cardiovascular disease that is not dissimilar from that of previously known diabetes...
  46. ncbi Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure
    M C Shibata
    Clinical Trials and Evaluation Unit, Royal Brompton and Harefield NHS Trust, Sydney Street, SW3 6NP, London, UK
    Eur J Heart Fail 3:351-7. 2001
    ..Further information on the effect of beta blockers in elderly patients and women would be helpful...
  47. ncbi 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaborat
    Elliott M Antman
    Circulation 117:296-329. 2008
  48. ncbi The management of heart failure in Sweden
    C M J Cline
    Department of Cardiology, Malmo University Hospital, Lund University, SE 205 02, Malmo, Sweden
    Eur J Heart Fail 4:373-6. 2002
    ..Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers appear to be under prescribed. Nurse-led heart failure clinics are being widely established in an attempt to curtail costs and improve management...
  49. ncbi Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)
    Marcus D Flather
    Clinical Trials and Evaluation Unit, Royal Brompton and Harefield NHS Trust, London, UK
    Eur Heart J 26:215-25. 2005
    ..The SENIORS study was performed to assess effects of the beta-blocker, nebivolol, in patients >/=70 years, regardless of ejection fraction...
  50. ncbi Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics
    Enrico Agabiti Rosei
    Department of Medical and Surgical Sciences, Clinica Medica, University of Brescia, Brescia, Italy
    Drugs 67:1097-107. 2007
    ....
  51. ncbi Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis
    Yvette R B M van Gestel
    Department of Anesthesiology, Erasmus Medical Center, Rotterdam, The Netherlands
    Am J Respir Crit Care Med 178:695-700. 2008
    ..There is a general reluctance to prescribe beta-blockers in patients with chronic obstructive pulmonary disease (COPD) because they may worsen symptoms...
  52. ncbi Use of beta-blockers and risk of fractures
    Raymond G Schlienger
    Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital, Basel, Switzerland
    JAMA 292:1326-32. 2004
    ....
  53. ncbi Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure
    Aina Hognestad
    Department of Cardiology, Rikshospitalet, University of Oslo, Oslo, Norway
    Am J Cardiol 93:603-6. 2004
    ..Early initiation of statins or beta blockers alone was associated with improved event-free survival, and the benefits of the combined treatment were additive...
  54. ncbi Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF)
    John Wikstrand
    Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, Goteborg, Sweden
    J Am Coll Cardiol 40:491-8. 2002
    ....
  55. ncbi Urban-rural differences in the quality of care for medicare patients with acute myocardial infarction
    K Sheikh
    Health Care Financing Administration, 601 E 12th St, Room 227, Kansas City, MO 64106, USA
    Arch Intern Med 161:737-43. 2001
    ..There are urban-rural differences in health care utilization in Kansas. This study was conducted to determine if similar differences exist in the quality of inpatient care provided for patients with acute myocardial infarction (AMI)...
  56. ncbi Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction
    Gunnar H Gislason
    Department of Cardiovascular Medicine, Bispebjerg University Hospital, Bispebjerg Bakke 23, DK 2400 Copenhagen NV, Denmark
    Eur Heart J 27:1153-8. 2006
    ..To study initiation, dosages, and compliance with beta-blockers, angiotensin-converting enzyme (ACE)-inhibitors, and statins in patients after acute myocardial infarction (AMI) and to identify likely targets for improvement...
  57. ncbi Effect of beta-blockade on heart rate variability in decompensated heart failure
    D Aronson
    Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Int J Cardiol 79:31-9. 2001
    ..6+/-1.5 vs. 19.0+/-5.3, P=0.04). CONCLUSIONS: beta-blockers improve the impaired cardiac autonomic regulation during high sympathetic stress of decompensated heart failure...
  58. ncbi Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials
    Steven Joseph Haas
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, Australia
    Am Heart J 146:848-53. 2003
    ....
  59. ncbi Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease
    Peter A McCullough
    Department of Basic Science, Cardiology Section, University of Missouri Kansas City, School of Medicine, Truman Medical Center, Kansas City, MO 64108, USA
    Am Heart J 144:226-32. 2002
    ....
  60. ncbi Barriers to diagnosing and managing heart failure in primary care
    Susan M Phillips
    National Institute of Clinical Studies, Melbourne, Vic
    Med J Aust 181:78-81. 2004
    ..To explore potential barriers to the optimal diagnosis and management of heart failure in primary care...
  61. ncbi Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the central nucleus of the amygdala
    Francesco Leri
    Center for Studies in Behavioral Neurobiology, Concordia University, H3G 1M8, Montreal, Quebec, Canada
    J Neurosci 22:5713-8. 2002
    ....
  62. ncbi Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes
    Jean Pierre Bassand
    Eur Heart J 28:1598-660. 2007
  63. pmc The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors
    Jillian G Baker
    Institute of Cell Signalling, C Floor Medical School, Queen s Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
    Br J Pharmacol 144:317-22. 2005
    ..There is therefore considerable potential for developing more selective beta-antagonists for clinical use and thereby reducing the side-effect profile of beta-blockers...
  64. ncbi Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET
    Willem J Remme
    Sticares Cardiovascular Research Institute, Rhoon, The Netherlands
    J Am Coll Cardiol 49:963-71. 2007
    ..We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study...
  65. ncbi The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers
    Simon D R Thackray
    Department of Academic Cardiology, University of Hull, Castle Hill Hospital, Kingston upon Hull, United Kingdom
    Am Heart J 152:713.e9-13. 2006
    ..Beta-blockers are effective for the treatment of heart failure, but their mechanism of action is unresolved. Heart rate reduction may be a central mechanism or a troublesome side effect...
  66. ncbi Anti-adrenergic effects of endothelin on human atrial action potentials are potentially anti-arrhythmic
    Calum J Redpath
    Division of Cardiovascular and Medical Sciences, University of Glasgow, UK
    J Mol Cell Cardiol 40:717-24. 2006
    ....
  67. ncbi A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial
    Carl J Pepine
    Division of Cardiovascular Medicine, Department of Medicine, University of Florida College of Medicine, Gainesville 32610, USA
    JAMA 290:2805-16. 2003
    ..Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials...
  68. ncbi The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis
    Pascal de Groote
    Service de Cardiologie C, Hopital Cardiologique, Centre Hospitalier Regional et Universitaire de Lille, Boul Prof J Leclercq, Lille Cedex, France
    Am Heart J 154:589-95. 2007
    ..No study has demonstrated that LVEF improvement was an independent predictor of cardiac survival...
  69. ncbi Does carvedilol impair insulin sensitivity in heart failure patients without diabetes?
    Stefania Ferrua
    University Department of Cardiology, San Giovanni Battista Hospital, Turin, Italy
    J Card Fail 11:590-4. 2005
    ..In this study, the metabolic effect of carvedilol in nondiabetic patients with chronic heart failure (CHF) was evaluated...
  70. ncbi Effect of carvedilol on survival in severe chronic heart failure
    M Packer
    Division of Circulatory Physiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    N Engl J Med 344:1651-8. 2001
    ..Beta-blocking agents reduce the risk of hospitalization and death in patients with mild-to-moderate heart failure, but little is known about their effects in severe heart failure...
  71. ncbi Beta-blockers reduce bone resorption marker in early postmenopausal women
    Julie A Pasco
    The University of Melbourne, Department of Clinical and Biomedical Sciences Barwon Health, Geelong
    Ann Hum Biol 32:738-45. 2005
    ..There is evidence to suggest that beta-blockers used in the management of cardiovascular disease may also modulate bone metabolism and reduce bone fragility...
  72. ncbi Quality of life and antihypertensive effect with nebivolol and losartan
    Luc M Van Bortel
    Am J Hypertens 18:1060-6. 2005
    ..Quality of life and antihypertensive effect, two important therapeutic goals, were determined with the third generation beta-blocker nebivolol and the angiotensin receptor blocker losartan are compared...
  73. ncbi beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 20:613-8. 2005
    ..We studied the association of beta-blocker use with BMD and fractures in the Study of Osteoporotic Fractures. beta-blocker use and BMD are unrelated in this cohort, and associations with fracture risk are inconsistent...
  74. ncbi Betaxolol, a beta1-adrenoceptor antagonist, has an affinity for L-type Ca2+ channels
    J Melena
    Nuffield Laboratory of Ophthalmology, University of Oxford, UK
    Eur J Pharmacol 378:317-22. 1999
    ..The ability of betaxolol to interact with L-type Ca2+ channels may have a role in its therapeutic effects in the management of systemic hypertension and in reducing neuronal death as occurring in glaucoma...
  75. ncbi Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients
    T J Cleophas
    Department Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands
    Am J Ther 13:192-7. 2006
    ..The efficacy of nebivolol as monotherapy and as the efficacy as add-on therapy are very similar. Nebivolol is highly efficacious in patients with ISH...
  76. ncbi Beta-blockers increase bone mineral density
    Sonay Turker
    Department of Cardiology, Dokuz Eylul University Hospital, Izmir, Turkey
    Clin Orthop Relat Res 443:73-4. 2006
    ..85 +/- 0.13, 0.80 +/- 0.11 and 0.90 +/- 0.15, 0.83 +/- 0.12, respectively. Our results suggest that use of beta-blockers is associated with an increase in bone mineral density...
  77. ncbi The beta-1 adrenergic antagonist, betaxolol, improves working memory performance in rats and monkeys
    Brian P Ramos
    Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06520 8001, USA
    Biol Psychiatry 58:894-900. 2005
    ..The current study examined the effects of the selective beta-1 antagonist, betaxolol, on working memory in rats and monkeys...
  78. ncbi Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial
    Bernard R Chaitman
    Department of Medicine, Division of Cardiology, St Louis University School of Medicine, St Louis, MO, USA
    JAMA 291:309-16. 2004
    ....
  79. ncbi Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers
    James O O'Neill
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 111:2313-8. 2005
    ..Beta-blockers reduce mortality in patients with heart failure, without influencing peak VO2, raising the possibility that peak VO2 is no longer suitable as an indicator of prognosis in these patients...
  80. ncbi Fracture risk in perimenopausal women treated with beta-blockers
    Lars Rejnmark
    Dept of Endocrinology and Metabolism C, Aarhus Amtssygehus, Aarhus University Hospital, Aarhus, Denmark
    Calcif Tissue Int 75:365-72. 2004
    ..beta-Blockers may decrease the activity of bone-forming cells and thereby increase fracture risk. However, confirmative studies and studies exploring mechanisms of action are needed...
  81. ncbi Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers
    K Masur
    Institute for Immunology, Witten Herdecke University, Witten, Germany
    Cancer Res 61:2866-9. 2001
    ..In summary, norepinephrine-induced locomotion of SW 480 cells is beta2-adrenoceptor mediated and distinct from spontaneous locomotion concerning the PTK involvement...
  82. ncbi Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure
    H N Sabbah
    Department of Medicine, Henry Ford Heart and Vascular Institute, Detroit, Michigan, USA
    J Am Coll Cardiol 36:1698-705. 2000
    ..The purpose of this study was to determine if therapy with beta-blockade is associated with reduced cardiomyocyte apoptosis...
  83. ncbi National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program
    Dale R Burwen
    Centers for Medicare and Medicaid Services, Baltimore, MD, USA
    Arch Intern Med 163:1430-9. 2003
    ..Furthermore, the variability of the recent change over time is not known...
  84. ncbi Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus
    Savina Nodari
    Cattedra di Cardiologia, Universita di Brescia, Piazza Spedali Civili, 25100 Brescia, Italy
    Eur J Heart Fail 5:803-9. 2003
    ..Diabetes is frequently associated with heart failure and is an independent risk factor for an increased mortality and morbidity. Beta-blockers are traditionally regarded as relatively contraindicated in patients with diabetes mellitus...
  85. ncbi Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF
    Prakash C Deedwania
    Department of Veterans Affairs Medical Center, Fresno, Calif, USA
    Am Heart J 149:159-67. 2005
    ....
  86. ncbi Clinical efficacies of antihypertensive drugs
    Ivar Aursnes
    Department of Pharmacotherapeutics, University of Oslo, Norway
    Scand Cardiovasc J 37:72-9. 2003
    ..We therefore explored the possibility of drawing statistically valid conclusions about the differences in clinical efficacy between various drug groups by doing an overview of published data...
  87. ncbi Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias
    P J Schwartz
    Department of Cardiology, Policlinico S Matteo IRCCS and University of Pavia, Pavia, Italy
    Circulation 103:89-95. 2001
    ..Preliminary observations suggested that the conditions ("triggers") associated with cardiac events may in large part be gene specific...
  88. ncbi Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis
    Bruce M Psaty
    Department of Medicine, University of Washington, Seattle, USA
    JAMA 289:2534-44. 2003
    ..Establishing relative benefit or harm from specific antihypertensive agents is limited by the complex array of studies that compare treatments. Network meta-analysis combines direct and indirect evidence to better define risk or benefit...
  89. ncbi Differential effects of antihypertensive drug therapy on arterial compliance
    Lawrence M Resnick
    Hypertension Center, New York Presbyterian Hospital Cornell University Medical Center, New York, New York 10021, USA
    Am J Hypertens 15:1096-100. 2002
    ..We hypothesize that a greater clinical benefit may result from the preferential use of drugs that concomitantly improve arterial compliance...
  90. ncbi Respiratory function in the elderly and the effects of beta blockade
    A E Tattersfield
    Respiratory Medicine Unit, City Hospital, Nottingham, UK
    Cardiovasc Drugs Ther 4:1229-32. 1991
    ..There is a greater danger in the elderly that a past history of asthma may be overlooked or that bronchoconstriction from a beta-blocking drug is attributed to other causes...
  91. ncbi Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial
    Ian R Reid
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    J Clin Endocrinol Metab 90:5212-6. 2005
    ..beta-blockers increase bone mass in mice, and some observational studies have suggested a beneficial effect of these drugs on bone in humans..
  92. ncbi Effect of PCI on quality of life in patients with stable coronary disease
    William S Weintraub
    Christiana Care Health System, Newark, DE 19718, USA
    N Engl J Med 359:677-87. 2008
    ..It has not been clearly established whether percutaneous coronary intervention (PCI) can provide an incremental benefit in quality of life over that provided by optimal medical therapy among patients with chronic coronary artery disease...
  93. ncbi Testing the combination beta-blocker plus topiramate in refractory migraine
    J Pascual
    Service of Neurology, University Hospital, Salamanca, Spain
    Acta Neurol Scand 115:81-3. 2007
    ..To test treatment combining a beta-blocker plus topiramate in migraine patients previously resistant to the two medications in monotherapy...
  94. ncbi AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute
    Sidney C Smith
    J Am Coll Cardiol 47:2130-9. 2006
  95. ncbi Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review
    F H Messerli
    Department of Internal Medicine, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, LA 70121, USA
    JAMA 279:1903-7. 1998
    ..To assess antihypertensive efficacy of beta-blockers and their effects on cardiovascular morbidity and mortality and all-cause morbidity compared with diuretics in elderly patients with hypertension...
  96. pmc Validation of a model to predict all-cause in-hospital mortality in vascular surgical patients
    B M Biccard
    Department of Anaesthetics, Nelson R Mandela School of Medicine and Inkosi Albert Luthuli Central Hospital, Durban, South Africa
    Cardiovasc J Afr 19:303-8. 2008
    ..To develop and validate a pre- and postoperative model of all-cause in-hospital mortality in South African vascular surgical patients...
  97. ncbi Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II)
    William N Brodine
    Research Medical Center and Kansas City Heart Foundation, Kansas City, Missouri, USA
    Am J Cardiol 96:691-5. 2005
    ..42 to 0.44, p <0.01). In conclusion, beta blockers reduce the risk for VT or VF and improve survival in ICD-treated patients with ischemic cardiomyopathy...
  98. ncbi The truth and consequences of the COURAGE trial
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center the Lindner Research Center, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 50:1598-603. 2007
    ..An in-depth analysis of the COURAGE trial design and execution is provided...
  99. pmc Beta2-adrenergic receptor signaling mediates corneal epithelial wound repair
    Shahed Y Ghoghawala
    Department of Ophthalmology and Vision Science, School of Medicine, University of California Davis, One Shields Avenue, Davis, CA 95616, USA
    Invest Ophthalmol Vis Sci 49:1857-63. 2008
    ..Beta-adrenergic receptor (AR) antagonists are frequently prescribed ophthalmic drugs, yet previous investigations into how catecholamines affect corneal wound healing have yielded conflicting..
  100. ncbi Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial
    Z M Chen
    Clinical Trial Service Unit and Epidemiological Studies Unit CTSU, Richard Doll Building, Old Road Campus, Oxford OX3 7LF, UK
    Lancet 366:1622-32. 2005
    ....
  101. ncbi Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis
    Lars Hjalmar Lindholm
    Department of Public Health and Clinical Medicine, Umea University Hospital, Umea, Sweden
    Lancet 366:1545-53. 2005
    ..However, a preliminary analysis has shown that atenolol is not very effective in hypertension. We aim to substantially enlarge the data on atenolol and analyse the effect of different beta blockers...

Research Grants65

  1. Quantitative Assessment of Oxidative Metabolism in Brown Fat
    Otto Muzik; Fiscal Year: 2011
    ..Moreover, these studies will provide important physiological information about fat metabolism that will likely translate into novel pharmacological approaches for the treatment of obesity. ..
  2. Exploring the Feasibility of Computational Markers to Predict Atrial Fibrillation
    JAMES MARLOW BLUM; Fiscal Year: 2013
    ..These approaches will be validated on the data collected in Aim 1, and will be used to develop models based on non-parametric machine learning techniques to accurately assess PAF risk. ..
  3. ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
    Roberto Groszmann; Fiscal Year: 2003
    ....
  4. METABOLISM OF B-ADRENERGIC BLOCKERS--CHEMISTRY
    WENDEL NELSON; Fiscal Year: 1990
    ..Experiments will be done in vitro (fractions from rat homogenates and human liver) and in vivo (in rats). Limited experiments in human subjects are proposed...
  5. Post Coronary Bypass Atrial Arrhythmic Prediction Rule
    Rod Passman; Fiscal Year: 2006
    ..This project will be an integral part of the candidate?s career development plan and his maturation as an epidemiologist, cardiac electrophysiologist, and clinical investigator. ..
  6. ADRENERGIC CONTROL OF HEART & MUSCLE PHOSPHOFRUCTOKINASE
    TAG MANSOUR; Fiscal Year: 1990
    ..Through the use of specific alpha and beta adrenergic blockers we intend to ascertain the pharmacological nature of activation of this enzyme by epinephrine and its congeners...
  7. PILOCARPINE PRODRUGS WITH IMPROVED BIOAVAILABILITY
    TROY REAVES; Fiscal Year: 1990
    ..The phase I study will provide a strong foundation for further development in Phase 2. Benefits of the prodrug will include improved bioavailability, lower and less frequent dosage and improved patient compliance...
  8. METABOLIC STEREOISOMERIC INVERSION OF CHIRAL DRUGS
    Ching Shih Chen; Fiscal Year: 1993
    ..Similar approaches will be take to scrutinize the metabolic inversion of beta-adrenergic blockers...
  9. MUSCLE LACTATE PRODUCTION IN SEPSIS
    James James; Fiscal Year: 2004
    ..Results of these studies will clarify metabolic relationships that are important both in health and disease. ..
  10. ACTION - A CHF Trial Investigating Outcomes of Exercise
    Gregg Fonarow; Fiscal Year: 2006
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  11. Utility of a New Database to Study Drug Safety during Pregnancy
    SOKO SETOGUCHI IWATA; Fiscal Year: 2008
    ..This database based on large population-based follow-up data with linkable clinical birth data has the potential to enhance the safety of prescription drug use in pregnant women and their children. [unreadable] [unreadable] [unreadable]..
  12. Evaluating reasons for variations in LDL levels
    P Ho; Fiscal Year: 2003
    ..abstract_text> ..
  13. AASK Cohort Study
    George Bakris; Fiscal Year: 2007
    ..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
  14. Cardiac Parasympathetic Effect in Exercise and Recovery
    Jeffrey Goldberger; Fiscal Year: 2006
    ..abstract_text> ..
  15. Neurohormonal Blockade and Outcomes in Diastolic Heart Failure
    Ali Ahmed; Fiscal Year: 2010
    ..The proposed study will examine the effect of neurohormonal blockade in propensity matched OPTIMIZE-HF participants with diastolic heart failure. ..
  16. Inflammation and Injury in Obesity Hypertension in African American Adolescents
    Bonita Falkner; Fiscal Year: 2010
    ..abstract_text> ..
  17. REGULATION OF INTRAOCULAR PRESSURE AND OCULAR BLOOD FLOW
    John Liu; Fiscal Year: 2007
    ..New knowledge of ocular blood flow and lOP in patients would have implications for the better diagnosis and treatment of glaucoma. ..
  18. TGF-Beta, Glucose and Nephropathy in African Americans
    Bonita Falkner; Fiscal Year: 2007
    ..abstract_text> ..
  19. Altered Myocardial Fatty Acid Metabolism in Obesity
    Linda Peterson; Fiscal Year: 2007
    ..Such information will form the basis for more targeted studies designed to elucidate the mechanisms responsible for these abnormalities and potentially result in significant clinical benefit for humans with AO. ..
  20. Genetic Modulation of Left Ventricular Recovery
    Dennis McNamara; Fiscal Year: 2008
    ..Specific Aim 3 will examine other genetic loci which act as modifiers of the cytokine and neurohomonal response, in particular NOS2, NOS3 and aldosterone synthase. ..
  21. Neural circuitry of submissive behavior and treatment response in social anxiety
    Franklin Schneier; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  22. Combination Treatment for PTSD After the WTC Attack
    Franklin Schneier; Fiscal Year: 2008
    ..Findings may enhance public health through the study of maximization of treatment response for this serious and common psychiatric disorder. ..
  23. Calpains as Mediators of Cardiac Ischemic Injury
    Gerald W Dorn; Fiscal Year: 2010
    ..Collectively, these studies will apply state-of-the-art techniques for in vivo genetic manipulation, microphysiologic analysis, and biochemical assessment to achieve insight into the roles of myocardial calpains in health and disease. ..
  24. ACTION - A CHF Trial Investigating Outcomes of Exercise
    CHRISTOPHER O CONNOR; Fiscal Year: 2008
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  25. Cocaine effects on norepinephrine in amygdala
    Carla Rudoy; Fiscal Year: 2007
    ..1995) and the stress-induced relapse to cocaine use (Lu et al., 2001) may be mediated by the effects of cocaine on noradrenergic circuits originating from brainstem nuclei (e.g. locus coeruleus) to the amygdala. ..
  26. Androgens and Cardiovascular Risk in African Americans
    Bonita Falkner; Fiscal Year: 2005
    ..The results of this project can contribute to the development of prevention and earlier intervention strategies, including more specific therapeutic targets, for this high-risk minority population. ..
  27. PHOSPHOLIPASE C AND CARDIAC HYPERTROPHY
    GERALD DORN; Fiscal Year: 2005
    ..abstract_text> ..
  28. BIRTH WEIGHT EFFECT ON BLOOD PRESSURE IN LATE CHILDHOOD
    Bonita Falkner; Fiscal Year: 2001
    ..Alternatively, if post-natal/childhood parameters are the major determinants of later BP, then efforts should focus on effective preventive strategies in childhood, such as obesity. ..
  29. Heart Failure and Beta-Blocker Use in Older Adults
    Ali Ahmed; Fiscal Year: 2006
    ..abstract_text> ..
  30. Heart failure, chronic kidney disease, and renin-angiotensin system inhibition
    Ali Ahmed; Fiscal Year: 2009
    ....
  31. Dopamine function in social phobia & related conditions
    Franklin Schneier; Fiscal Year: 2006
    ..Better understanding of the neurocircuitry associated with GSP holds promise for improving diagnosis and treatment strategies. ..
  32. Topiramate for alcohol and cocaine dependence
    Kyle Kampman; Fiscal Year: 2008
    ..abstract_text> ..
  33. Perinatal Regionalization and Quality of Care
    Scott Lorch; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  34. REGULATION OF EXPRESSION OF NO SYNTHASE
    Louis Ignarro; Fiscal Year: 2002
    ..The proposed research represents a continuing long-term effort to elucidate the biological factors influencing the vascular and related actions of NO in health and disease. ..
  35. TNF-ALPHA REGULATION OF AT1 RECEPTOR & POST-MI FIBROSIS
    Barry Greenberg; Fiscal Year: 2003
    ..This information will provide important insights into the pathogenesis of post-MI fibrosis. ..
  36. Role of Ryanodine Receptors in Diabetic Cadiomyopathy
    Keshore R Bidasee; Fiscal Year: 2010
    ....
  37. ACTION - A CHF Trial Investigating Outcomes of Exercise
    Eugene Wolfel; Fiscal Year: 2005
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  38. Lipoprotein Utilization and Oxidation in CHF
    Ulrich P Jorde; Fiscal Year: 2010
    ..If our hypotheses can be proven, they may lead to developments of new therapies to improve exercise capacity and longevity in patients afflicted with CHF. ..
  39. The Lymphatic Continuum Conference
    Stanley Rockson; Fiscal Year: 2002
    ..On the second day of the symposium, attendance will be limited to a working nucleus of 50-60 invited participants in order to encourage open discussion and formulation of theoretical research agendas. ..
  40. Atrial Fibrillation: Incidence, Risk Factors, and Genetics
    SUSAN HECKBERT; Fiscal Year: 2010
    ..The ultimate goal of this research is to increase knowledge about AF risk factors and prognosis and to enhance prevention efforts and improve care for patients with AF. ..
  41. CYTOSTATIC ROLE OF THE ARGININE-NITRIC OXIDE PATHWAY
    Louis Ignarro; Fiscal Year: 2001
    ..The proposed research should advance our understanding of the biological role of NO synthase in regulating cell proliferation. ..
  42. Prevent/Kidney Disease/Minority Groups/Emerging Nations
    Keith Norris; Fiscal Year: 2003
    ..abstract_text> ..
  43. EARLY DETECTION OF GLAUCOMA DAMAGE
    Henry Jampel; Fiscal Year: 2004
    ..This assessment of the RTA and NFA will help to establish their utility as outcome measures for clinical management of glaucoma, epidemiological research, and clinical trials. ..
  44. Novel Therapies for Resistant FSGS
    Howard Trachtman; Fiscal Year: 2006
    ..The infrastructure that is established for the performance of this R21/R33 project should prove useful for the efficient assessment of additional novel therapies that will be developed in the future for patients with primary FSGS. ..
  45. Dietary Fiber and Cardiovascular Inflammatory Markers
    Dana King; Fiscal Year: 2006
    ..This information could serve to guide constructive changes in nutritional guidelines for reducing CVD risk for millions of at-risk individuals. ..
  46. Beta2 Adrenergic Receptor in Keratinocyte Migration
    CHRISTINE PULLAR; Fiscal Year: 2006
    ..abstract_text> ..
  47. Beta-receptors and cardiovascular pharmacogenomics
    Julie Johnson; Fiscal Year: 2006
    ..abstract_text> ..
  48. HEMORHEOLOGY STUDIES RELATED TO IN VIVO BLOOD FLOW
    HERBERT MEISELMAN; Fiscal Year: 2008
    ....
  49. Equipment Support for USD Laboratory Animal Services
    Douglas Martin; Fiscal Year: 2005
    ..The long-term goal is to achieve AAALAC accreditation. It is expected that AAALAC review for accreditation will be requested within 18 months of completion and occupancy of the new LAS. ..
  50. Effect of Daily Exercise on Cardiac Autonomic Regulation
    GEORGE BILLMAN; Fiscal Year: 2005
    ..Ventricular contractile responses to Beta1- and Beta2-adrenoceptor stimulation will be examined in vivo by echocardiography and in vitro by single cell fluorescence microscopy/video edge detection. ..
  51. Progestrone and the Effects of Nicotine
    Mehmet Sofuoglu; Fiscal Year: 2006
    ..By characterizing the progesterone effects on nicotine dependence, this study may provide a better understanding of the mechanisms which mediate the sex and menstrual cycle phase effects on nicotine dependence. ..
  52. Effect of lipid modification on peripheral arterial disease (PAD)
    Christie Ballantyne; Fiscal Year: 2007
    ..Finally, these studies will advance our understanding of the molecular mechanisms of inflammation and thrombosis associated with aggressive lipid modification. ..
  53. Myocardial Protein Synthesis After Thermal Injury
    Charles Lang; Fiscal Year: 2005
    ..Overall, the research will elucidate the mechanisms by which myocardial protein synthesis is reduced after thermal injury, leading to the better understanding and treatment of the resulting cardiomyopathy. - ..
  54. Urodynamic and Multiethnic Variability of Men Treated b*
    Steven Kaplan; Fiscal Year: 2005
    ..Baseline urodynamic parameters which may predict improved outcome after MIST 3. The success of various types of MIST in treating BPH in African - American, Hispanic and Caucasian men. ..
  55. Endothelial Dysfunction, Oxidative Stress and Risk of Peripheral Arterial Disease
    Kenneth Jay Mukamal; Fiscal Year: 2010
    ..Finally, we will examine how a derived dietary antioxidant score, based upon measured oxidative potential of specific foods using the ferric-reducing/antioxidant power method, is related to PAD. ..
  56. MODERATE ALCOHOL USE--CARDIOVASCULAR RISKS AND BENEFITS
    Thomas Giles; Fiscal Year: 2001
    ..The exacerbation or prevention of EIH will be related to drug effects on the cell-signaling pathway. This research can define the cell-signaling pathway in EIH and provide new and novel approaches to treating EIH. ..
  57. Angiotensin, Nitric Oxide and Target Organ Damage
    Daniel Catanzaro; Fiscal Year: 2005
    ..abstract_text> ..
  58. Prescription Drug Coverage and Health Outcomes in Elders
    Jennifer Tjia; Fiscal Year: 2008
    ..abstract_text> ..
  59. Heavy Drinking & Coronary Disease: Acute/Chronic Effects
    Kenneth Mukamal; Fiscal Year: 2006
    ..These results may prove to have important biological, clinical, and public health implications for the care of CHD. ..
  60. ESCAPE Mechanistic Substudies
    Robert Califf; Fiscal Year: 2003
    ..Catecholamines are also being collected at baseline and 3 months. In addition, the ESCAPE investigators are all ready capturing detailed demographic, clinical, and physiological information as part of the protocol for the primary study. ..